0
Meta-analysis | ONLINE FIRST

The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment:  Meta-analysis of Imaging Studies

Oliver D. Howes, BM, BCh, MA, MRCPsych, PhD, DM; Joseph Kambeitz, MD; Euitae Kim, MD, PhD; Daniel Stahl, PhD; Mark Slifstein, PhD; Anissa Abi-Dargham, MD; Shitij Kapur, MD, PhD
Arch Gen Psychiatry. 2012;69(8):776-786. doi:10.1001/archgenpsychiatry.2012.169.
Text Size: A A A
Published online

Context  Current drug treatments for schizophrenia are inadequate for many patients, and despite 5 decades of drug discovery, all of the treatments rely on the same mechanism: dopamine D2 receptor blockade. Understanding the pathophysiology of the disorder is thus likely to be critical to the rational development of new treatments for schizophrenia.

Objective  To investigate the nature of the dopaminergic dysfunction in schizophrenia using meta-analysis of in vivo studies.

Data Sources  The MEDLINE, EMBASE, and PsycINFO databases were searched for studies from January 1, 1960, to July 1, 2011.

Study Selection  A total of 44 studies were identified that compared 618 patients with schizophrenia with 606 controls, using positron emission tomography or single-photon emission computed tomography to measure in vivo striatal dopaminergic function.

Data Extraction  Demographic, clinical, and imaging variables were extracted from each study, and effect sizes were determined for the measures of dopaminergic function. Studies were grouped into those of presynaptic function and those of dopamine transporter and receptor availability. Sensitivity analyses were conducted to explore the consistency of effects and the effect of clinical and imaging variables.

Data Synthesis  There was a highly significant elevation (P < .001) in presynaptic dopaminergic function in schizophrenia with a large effect size (Cohen d = 0.79). There was no evidence of alterations in dopamine transporter availability. There was a small elevation in D2/3 receptor availability (Cohen d = 0.26), but this was not evident in drug-naive patients and was influenced by the imaging approach used.

Conclusions  The locus of the largest dopaminergic abnormality in schizophrenia is presynaptic, which affects dopamine synthesis capacity, baseline synaptic dopamine levels, and dopamine release. Current drug treatments, which primarily act at D2/3 receptors, fail to target these abnormalities. Future drug development should focus on the control of presynaptic dopamine synthesis and release capacity.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Grahic Jump Location

Figure 1. Studies of presynaptic dopaminergic function.19,25,36,3849 The forest plot shows the effect sizes and 95% CIs of the difference between patients with schizophrenia and controls, by study. There was evidence of a significant elevation in schizophrenia with a summary effect size of d = 0.79 (diamond).

Place holder to copy figure label and caption
Grahic Jump Location

Figure 2. Effect sizes for studies of presynaptic dopaminergic function, by antipsychotic treatment history. In the box plot, the horizontal line represents the median, the whiskers indicate the lowest and highest data points that are within 1.5 the interquartile range, and data outside this range (circles if present) are regarded as potential outliers.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 3. Studies of dopamine transporter availability.5161 The forest plot shows the effect sizes and 95% CIs of the difference between patients with schizophrenia and controls, by study. The 95% CI for the summary effect size (diamond; d = 0.34) includes 0, indicating no significant difference between patients with schizophrenia and controls.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 4. Studies of D2/3 receptor availability.14,36,4243,50,56,6277 The forest plot shows the effect sizes and 95% CIs of the difference between patients with schizophrenia and controls, by study. There was evidence of a small increase in D2 receptor availability in schizophrenia with a summary effect size (diamond) of d = 0.26.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 5. Schematic diagram summarizing the findings from our meta-analyses of dopamine function in schizophrenia. The diagram shows that the major dopaminergic abnormality in schizophrenia is presynaptic. The main findings from our meta-analyses are that presynaptic dopaminergic function is altered in schizophrenia, with a large effect size (d = 0.79), and that there is no difference in dopamine transporter availability and a small elevation in D2/3 receptor availability, although the latter finding was not consistent.

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs